Clinical Trials Browser

Phase 1/2 × OTHER × Cisplatin × Clear all

NCT03734692 2026-02-12

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

Phase 1/2 Active not recruiting

24 enrolled 59 charts

Ovarian Cancer Recurrent

NCT07392541 2026-02-06

Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer

Phase 1/2 Recruiting

Gastrointestinal

Advanced Biliary Tract Carcinoma

NCT06548412 2026-01-20

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

Phase 1/2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT02989584 2026-01-07

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04203160 2025-12-31

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

Phase 1/2 Terminated

75 enrolled 17 charts

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04711824 2025-12-23

SOLARA

Phase 1/2 Recruiting

Brain Neoplasms, Breast Neoplasms

NCT05664971 2025-12-02

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Phase 1/2 Completed

Advanced Lung Cancer

NCT06040970 2025-12-02

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

Phase 1/2 Recruiting

Ovarian Neoplasms, Uterine Neoplasms

NCT02393794 2025-10-06

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Phase 1/2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06531434 2025-09-22

Establishing Best Treatment Strategy for T4 Esophageal Cancer

Phase 1/2 Recruiting

Gastrointestinal

Esophageal Cancer TNM Staging Primary Tumor (T) T4

NCT02432378 2025-06-19

Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines

Phase 1/2 Terminated

Ovarian Neoplasms

NCT06802835 2025-05-16

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Phase 1/2 Recruiting

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT06956716 2025-05-04

Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma

Phase 1/2 Recruiting

Gastrointestinal

Advanced Intrahepatic Cholangiocarcinoma

NCT02365766 2025-03-18

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects

Phase 1/2 Completed

83 enrolled 14 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05784012 2025-03-13

RADIAN

Phase 1/2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06494943 2025-02-25

Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC

Phase 1/2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02202772 2025-02-24

CGC

Phase 1/2 Active not recruiting

Carcinoma, Neoplasms, Recurrence

NCT04278287 2024-12-13

Chemoradiotherapy in Unresectable Esophageal Cancer

Phase 1/2 Recruiting

Gastrointestinal

Esophageal Neoplasms

NCT04989218 2024-11-05

ICC

Phase 1/2 Terminated

1 enrolled 11 charts

Gastrointestinal

Cholangiocarcinoma

NCT03277924 2024-08-13

ImmunoSarc

Phase 1/2 Completed

Chondrosarcoma, Extraskeletal Myxoid, Bone Neoplasms, Chondrosarcoma, Hemangioendothelioma, Hemangiosarcoma, Leiomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Hemangioendothelioma, Epithelioid, Histiocytoma, Malignant Fibrous, Solitary Fibrous Tumors

NCT03319537 2024-05-23

Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma

Phase 1/2 Terminated

9 enrolled 9 charts

Other solid neoplasmThoracic

Mesothelioma

NCT06217757 2024-05-13

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Phase 1/2 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT01088347 2024-04-19

Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer

Phase 1/2 Completed

Uterine Cervical Neoplasms

NCT03246750 2024-04-17

B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma

Phase 1/2 Completed

Lymphoma, Extranodal NK-T-Cell

NCT00889733 2024-03-26

OVHM-01

Phase 1/2 Terminated

Carcinoma, Ovarian Epithelial

NCT06173986 2023-12-18

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

Phase 1/2 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03649321 2023-11-09

Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer

Phase 1/2 Terminated

9 enrolled 12 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02324543 2023-07-21

Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer

Phase 1/2 Completed

47 enrolled 22 charts

Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT05898256 2023-06-12

Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 1/2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT03410030 2023-04-18

AA NABPLAGEM

Phase 1/2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT04646837 2023-03-29

Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05441761 2022-07-01

Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL

Phase 1/2 Unknown

Lymphoma, T-Cell, Peripheral

NCT01076231 2021-05-17

Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery

Phase 1/2 Completed

34 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT02759575 2021-03-12

A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma

Phase 1/2 Completed

9 enrolled 11 charts

Head and Neck Neoplasms

NCT02992340 2021-01-14

Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC

Phase 1/2 Terminated

Gastrointestinal

Biliary Tract Neoplasms

NCT02604784 2020-09-17

PI-CaP

Phase 1/2 Completed

Peritoneal Neoplasms

NCT00851877 2020-08-21

Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer

Phase 1/2 Completed

37 enrolled 9 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Tongue Neoplasms

NCT00003086 2020-07-14

Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer

Phase 1/2 Terminated

Breast Neoplasms

NCT00589056 2020-04-24

Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Phase 1/2 Completed

55 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03706287 2020-04-06

Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01614132 2020-03-31

NOA-07

Phase 1/2 Completed

Medulloblastoma, Neoplasms, Neuroectodermal Tumors

NCT02801487 2020-02-17

Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma

Phase 1/2 Terminated

Nasopharyngeal Carcinoma

NCT00565370 2020-01-18

Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP

Phase 1/2 Completed

22 enrolled 11 charts

Gastrointestinal

Stomach Neoplasms

NCT03697239 2019-06-11

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Phase 1/2 Withdrawn

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT03797443 2019-05-31

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Phase 1/2 Withdrawn

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT03908333 2019-05-30

High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Phase 1/2 Withdrawn

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT01893801 2019-05-29

Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA

Phase 1/2 Completed

25 enrolled 17 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01230996 2019-04-24

DEPICT

Phase 1/2 Completed

Uterine Cervical Neoplasms

NCT02243436 2019-04-24

Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma

Phase 1/2 Completed

Hodgkin Disease, Lymphoma

NCT01083537 2019-02-15

Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction

Phase 1/2 Terminated

Fallopian Tube Neoplasms, Intestinal Obstruction, Ovarian Neoplasms